Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialHelen M. Colhoun, John Fuller, Margaret J. Thomason et al.|The Lancet|2004Cited by 3.8k
Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS)Helen M. Colhoun, John Fuller, D. J. Betteridge et al.|American Journal of Kidney Diseases|2009Cited by 253
Total Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 DiabetesHelen M. Colhoun, John Fuller, Kathryn Choon Beng Tan et al.|Diabetes|2011Cited by 162